SCHEMBL6801641

SCHEMBL6801641

CN1[C@@H]2CC[C@H]1C[C@H](N(C(=O)O)C1CN(C(c3ccccc3)c3ccccc3)C1)C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C9 P11712 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CHRM2 P08172 5/20 0.44
CHRM5 P08912 5/20 0.44
CHRM1 P11229 5/20 0.44
CHRM3 P20309 5/20 0.44
CHRM4 P08173 4/20 0.44
BLM P54132 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HTR2C P28335 3/20 0.43
ADRA2C P18825 2/20 0.43
ADRA1A P35348 2/20 0.43
HRH1 P35367 2/20 0.43
ADRA1D P25100 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6801650 1.00 LMNA (0.45) LMNACYP2D6CYP2C9HSD17B10CHRM2
SCHEMBL6794816 0.85 CHRM2 (0.43) LMNACYP2D6CYP2C9HSD17B10CHRM2
SCHEMBL6794820 0.85 CHRM2 (0.43) LMNACYP2D6CYP2C9HSD17B10CHRM2
SCHEMBL4594597 0.85 ALDH1A1 (0.47) MEN1KMT2AKDM4EPOLBMAPT
SCHEMBL1221934 0.75 KMT2A (0.49) CYP2D6CYP2C9CHRM2CHRM5CHRM1
SCHEMBL6800935 0.71 SLC6A2 (0.50) LMNACYP2D6CYP2C9HSD17B10CHRM2
SCHEMBL3317446 0.71 KMT2A (0.48) LMNACYP2D6CYP2C9MEN1KMT2A
SCHEMBL5074955 0.71 OPRD1 (0.52) MEN1KMT2APOLBOPRM1OPRD1
SCHEMBL4594424 0.71 CCR5 (0.42) MEN1KMT2AMAPTOPRM1OPRD1
SCHEMBL13778878 0.71 KMT2A (0.50) CYP2D6CYP2C9MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734306-B2 USEFUL IN THE TREATMENT OF INFLAMMATION, ASTHMA, ALLERGIC RHINITIS, PAIN OR THE LIKE PFIZER, INC. 2004-05-11 US disclosed
US-20020128271-A1 N-benzenesulfonyl l-proline compounds as bradykinin antagonists PFIZER INC. 2002-09-12 US disclosed
EP-1213289-A1 N-benzenesulfonyl L-proline compounds as bradykinin antagonists PFIZER INC. (US) 2002-06-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128271-A1 N-benzenesulfonyl l-proline compounds as bradykinin antagonists BDKRB1, HRH2, BDKRB2 LMNA 1563/4885CYP2D6 2011/4885CYP2C9 1582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.